Key result
Aspirin for primary ASCVD prevention in women requires shared decision-making under updated recommendations.
Why the study?
Does aspirin prevent atherosclerotic cardiovascular disease in women when used for primary prevention?
Does aspirin prevent atherosclerotic cardiovascular disease in women when used for primary prevention?
This clinical update highlights updated recommendations and the importance of shared clinical decision-making for aspirin use in the primary prevention of ASCVD in women.
Answers are grounded in this paper and cite their sources.
Encourages individualized aspirin decisions in women; leaves open the need for dedicated primary prevention trials by sex.
This JAMA Insights Clinical Update discusses updated recommendations on the use of aspirin for primary prevention of atherosclerotic cardiovascular disease in women and stresses the importance of shared clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Shufelt et al. (2022) studied this question. Aspirin use for the primary prevention of atherosclerotic cardiovascular disease in women should be guided by updated recommendations emphasizing shared clinical decision-making.
Synapse has enriched 10 related papers. Consider them for comparative context: